Background: Ferritin is an iron storage protein essential for iron homeostasis regulation and an indicator of iron stores. It is an acute phase reactant and is elevated in inflammation and chronic infection. Periodontitis is a chronic inflammatory disease with periodontopathogens possessing haemolytic activity which leads to increased local iron concentration and iron disorder. Inflammation and excess systemic iron are mediating risk factors of type 2 diabetes mellitus.
Aim: To evaluate and compare the salivary ferritin levels in subjects with chronic periodontitis with and without type 2 diabetes mellitus.
Methodology: Unstimulated saliva sample was collected by standardized spitting technique from 45 individuals, aged between 30 and 65 years divided into three groups. Group I-Healthy individuals, Group II-Subjects with chronic periodontitis with type 2 diabetes mellitus, Group III-Subjects with chronic periodontitis without type 2 diabetes mellitus. The salivary ferritin levels are analysed using latex-enhanced turbidimetric assay in an autoanalyzer.
Results: The salivary ferritin level was elevated in chronic periodontitis with type 2 diabetes mellitus (Group II) and in chronic periodontitis without type 2 diabetes mellitus (Group III).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4103/ijdr.ijdr_211_24 | DOI Listing |
Crit Rev Food Sci Nutr
March 2025
Department of Food Science and Nutrition, The Hong Kong Polytechnic University, Hong Kong SAR, China.
This study aims to review the evidence from Mendelian randomization (MR) studies on the causal role of vitamin D in type 2 diabetes (T2D). A systematic search (registered on PROSPERO (CRD42024551731)) was performed in PubMed, Embase and Web of Science for publications up to June 2024. MR studies including vitamin D as the exposure and T2D as the outcome were included.
View Article and Find Full Text PDFLiver Int
April 2025
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common chronic liver disease globally. MASLD is a multisystem disease where metabolic dysfunction plays a key role in the development of MASLD and its most relevant liver-related morbidities and extrahepatic complications, such as cardiovascular disease, chronic kidney disease and certain types of extrahepatic cancers. Among the least examined MASLD-related extrahepatic complications, an ever-increasing number of observational studies have reported a positive association between MASLD and the risk of serious bacterial infections (SBI) requiring hospital admission.
View Article and Find Full Text PDFCells
March 2025
Fondazione CNR-Regione Toscana G Monasterio, Via G. Moruzzi 1, 56124 Pisa, Italy.
In recent years, new drugs for the treatment of type 2 diabetes (T2D) have been proposed, including glucagon-like peptide 1 (GLP-1) agonists or sodium-glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors. Over time, some of these agents (in particular, GLP-1 agonists and SGLT2 inhibitors), which were initially developed for their glucose-lowering actions, have demonstrated significant beneficial pleiotropic effects, thus expanding their potential therapeutic applications. This review aims to discuss the mechanisms, pleiotropic effects, and therapeutic potential of GLP-1, DPP-4, and SGLT2, with a particular focus on their cardiorenal benefits beyond glycemic control.
View Article and Find Full Text PDFAdv Mater
March 2025
PCFM Lab, School of Chemistry, Sun Yat-sen University, Guangzhou, 510006, P. R. China.
Exudate management and cell activity enhancement are vital to complicated wound healing. However, current exudate management dressings indiscriminately remove exudate, which is detrimental to cell activity enhancement. Herein, a novel class of electroactive bilayer (cMO/PVA) dressing is developed by constructing manganese oxide nanoneedle-clusters decorated commercial carbon cloth (MO), in situ casting polyvinyl alcohol (PVA) hydrogel, and finally charging.
View Article and Find Full Text PDFAnn Pharmacother
March 2025
Collegium Medicum, Jan Kochanowski University, Kielce, Poland.
Objective: To summarize the current knowledge on the therapeutic potential of GLP-1 receptor agonists in managing metabolic associated steatotic liver disease (MASLD).
Data Sources: A literature review was conducted using the search terms , , , , , and on PubMed (from January 1, 2019, through February 1, 2025), National Institutes of Health (NIH) (from January 1, 2019, through February 1, 2025), Scopus (from January 1, 2019, through February 1, 2025), and the World Health Organization (WHO) data.
Study Selection And Data Extraction: All relevant clinical trials, review articles, package inserts, and guidelines evaluating clinically relevant evidence regarding the therapeutic potential of GLP-1 agonists in MASLD were considered for inclusion.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!